Tenax Therapeutics, Inc. (TENX) Stock Analysis & Investment Frameworks

Tenax Therapeutics, Inc. (TENX) stock analysis on Invetso. Review Tenax Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Tenax Therapeutics, Inc. Company Overview

Tenax Therapeutics, Inc. Key Financial Metrics

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.

Tenax Therapeutics, Inc. Investment Frameworks

Invetso analyzes Tenax Therapeutics, Inc. (TENX) across the following frameworks:

Explore More TENX Research